HIV Resource Materials for Physicians
Compiled by MATEC Michigan
Jun 17, 2019
RECENT UPDATES:
Jun 17, 2019 Guidelines for Prevention and Treatment of Opportunistic
Infections in HIV-Infected Adults and Adolescents Section 6 A
TABLE OF CONTENTS
Section 1: Pathogenesis
A) HIV Overview: Pathogenesis and Natural History of
HIV/AIDS (Jon Cohn, MD, September 2006) (Click Here)
Section 2: Antiretroviral Treatment
A) Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults And Adolescents (US Department of Health and Human Services, October, 2018)(Click Here)
B) Antiretroviral Treatment of Adult HIV Infection: Recommendations of the IAS-USA Panel (2018) (Click Here)
C) Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Department of health and Human Services (HHS) Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, December 2018)
D) Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (US Department of Health and Human Services, Apr 2019) (Click Here)
Section 3: Adherence
A) Adherence to Potent Antiretroviral Therapy (October, 2004) (Click Here)
B) Promoting Adherence to Antiretroviral Therapy (AIDS Institute, New York State, Department of Health) (Click Here)
C) Model of Adherence Workshop (J, Fisher, Ph.D., June 2000) (Click Here)
Section 4: Drug Resistance
A) Update of the Drug Resistance Mutations in HIV-1: 2011 (International AIDS Society – USA, Topics in HIV Medicine, 1; March 2013) (Click Here)
B) Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of
an International AIDS Society-USA Panel (Click Here)
Section 5: HIV Patient Care
A) Primary Care Guidelines for the Management of Persons infected with Human
Immunodeficiency Virus: 2013 Update by the HIV Medicine Association of the Infectious
Diseases Society of America (2014) (Click Here)
B) Initial Work-Up of HIV Infected Adult (Jon Cohn, MD, Aug 2016)
Recommended Health Maintenance (Jon Cohn, MD, Aug 2016) (Click Here)
C) Michigan AIDS Drug Assistance Program formulary (February 1, 2013) (Click Here)
D) Kidney disease in HIV infected patients (Oct 24, 2012) (Click Here)
E) Cholesterol guidelines at a glance (National Cholesterol Education Program ATP III, 2004) (Click Here)
F) Retention in HIV care: Patient-Centered Strategies( Click Here)
G) What clinicians should know about retention in HIV care Giordano (2010) (Click Here)
H) Essential Components of HIV, Gallant for HIVMA (Oct 2012) (Click Here)
Section 6: Opportunistic Infections
A) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (Recommendations of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA); Nov, 2018) (Click Here)
B) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Children (Recommendations of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA), the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics, December, 2016) (Click Here)
Section 7: HIV Prevention
A) Incorporating HIV Prevention into the Medical Care of Persons Living with HIV (CDC, HRSA, NIH,and IDSA, July 2003) (Click Here)
B) Updated US Public Service Health Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Post Exposure Prophylaxis (Recommendations of the US Department of Health and Human Services, Sep 2013) (Click Here)
C) Antiretroviral Post Exposure Prophylaxis, After Sexual Injecting Drug Use, or other Non-Occupational Exposure to HIV in the United States (Recommendations of the US Department of Health and Human Services, April 2016) (Click Here)
D) Preexposure Prophylaxis for the Prevention of HIV infection in the Unites States – CDC, 2014 Clinical Practice Guideline) (Click Here)
E) Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – Clinical Provider’s Supplement (CDC, 2014 Clinical Practice Guideline) (Click Here)
F) PrEP Fact Sheet (CDC May 2014) (Click Here)
G) MDHHS PrEP Provider Toolkit (Click Here)
H) MDHHS Guidance for Administration of HIV nPEP (Non-Occupational Post-Exposure Prophylaxis (June 2015) (Click Here)
I) MDHHS nPEP Guidance Excerpts (June 2015) (Click Here)
J) MDHHS Perinatal HIV, HBV and Syphilis Guidelines (Click Here)
Section 8: STD Guidelines
A) Sexually Transmitted Disease Treatment Guidelines (Department Of Health and Human Services Center for Disease Control and Prevention, June 2015)(Click Here)
Section 9: Tuberculosis
A) Treatment of Tuberculosis (American Thoracic Society, CDC and IDSA, Aug 2016) (Click Here)
B) Managing Drug Interactions in the Treatment of HIV-related Tuberculosis (CDC, June 2013) (Click Here)
Section 10: Hepatitis
A) Chronic Hepatitis B (AASLD Practice Guidelines, September 2009) (Click Here)
B) Care of HIV patients with Chronic Hepatits B (Recommendations of the National Institutes of Health (NIH), the Centers for Diseases Control and Prevention (CDC), and the HIV Medicine Associations of the Infectious Diseases Society of America (HIVMA/IDSA); Apr 16, 2015) (Click Here)
C) Diagnosis, Management, and Treatment of Hepatitis C: An Update (AASLD Practice Guidelines, Sep 2016) (Click Here)
D) MDHHS Perinatal HCV Toolkit (Click Here)
Section 11: HIV Testing
A) Michigan HIV Laws for Health Care Providers (MDCH, January 2006) (Click Here)
B) Position Statement: HIV Screening in Health Care Settings (MDCH, March 2007) (Click Here)
C) Questions and Answers about HIV Screening in Health Care Settings (Division of Health Wellness & Disease Control, MDCH; March 2007) (Click Here)
D) CDC Screening Guidelines Comparison to Michigan (Click Here)
E) Routine Testing: Sample Consent to Treatment Form (Click Here)
F) Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings (The Centers for Disease Control and Prevention (CDC), September 22, 2006) (Click Here)
G) Laboratory Testing for the Diagnosis of HIV Infection Settings (The Centers for Disease Control and Prevention (CDC), June 27, 2014) (Click Here)
H) New Recommendations for HIV Testing in Laboratories: A Step by Step account of the approach (The Centers for Disease Control and Prevention (CDC), June, 2014) (Click Here)
I) Advantages and Disadvantages of FDA-approved HIV Immunoassays Used for Screening by Generation and Platform (The Centers for Disease Control and Prevention (CDC), June 23, 2014) (Click Here)
Section 12: HIV Clinical Manuals
A) Clinical Manual for the Management of the HIV Infected Adult (AIDS Education and Training Centers, April 2014) (Click Here)
B) A Guide to the Clinical Care of Women with HIV (Edited by Jean R. Anderson, MD, November 2013) (Click Here)
Section 13: Drug Charts
A) POZ Antiretroviral Drug Chart 2017 (Click Here)
Section 14: HIV Resources
A) List of On-line HIV Resources (Click Here)
B) List of National Resources (Click Here)
C) Sample Consent Forms for HIV Testing:
English (Click Here)
Bengali Click Here)
Spanish (Click Here)
Arabic (Click Here)
D) HIV Education Videos for Clinicians:
1. Antiretroviral Therapy (Click Here)
2. Guidelines for Michigan Clinicians: Non-Occupational
HIV Post Exposure Prophylaxis and Testing/Reporting
Perinatal HIV, Syphilis and HBV (Click Here)
3. HIV and Adult Primary Care (Click Here)